The online interaction and matchmaking systems of euroPLX Conferences provide 25 to 30 pre-arranged business meetings per attending company. It is the preferred partnering platform for new business opportunities since almost 24 years. Information exchange and interaction between confirmed registrants starts right after registration, intensifying during the month before the conference with two days of targeted, pre-scheduled one-on-one meetings of top executives of drug developing, producing or marketing companies from all over the world.

The partnering scope ranges from prescription to OTC drugs, companion diagnostics, nutraceuticals, and medical devices: development, licensing, marketing, promotion, and distribution. The “Dynamic Partnering Focus” of this conference shows up on this page as soon as a sufficient number of collaboration interests are submitted. In addition, attending companies may offer or look for R&D services, supporting technologies (e.g. new drug delivery), contract manufacture, and the supply of APIs and intermediates.

We’re looking forward to attending this event and hope to see you there!

Additional News

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.